Patents by Inventor Scott Kopetz

Scott Kopetz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR DUPLEX SEQUENCING OF CELL-FREE DNA AND APPLICATIONS THEREOF
    Publication number: 20220356467
    Abstract: Provided herein are methods of preparing cell-free DNA (cfDNA) for sequencing such that variant allele frequencies are maintained. Also provided are sequencing libraries prepared according to such methods. In addition, methods are provided for analyzing sequencing reads to determine variant allele frequencies. These methods may be used for diagnosing and/or evaluating cancer patients.
    Type: Application
    Filed: June 25, 2020
    Publication date: November 10, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventors: Rajyalakshmi LUTHRA, Dzifa Y. DUOSE, Scott KOPETZ, Ignacio I. WISTUBA, Stephanie ZALLES, Saradhi MALLAMPATI
  • COLORECTAL CANCER CONSENSUS MOLECULAR SUBTYPE CLASSIFIER CODESETS AND METHODS OF USE THEREOF
    Publication number: 20220180974
    Abstract: Provided herein is a consensus molecular subtype (CMS) classifier for colorectal cancer patients. Also provided are methods of using the classifier to identify a clinically beneficial therapeutic regime for each patient as well as methods of treating a patient accordingly Custom Nanostring code sets, which work on formalin-fixed, paraffin-embedded samples, are provide for use in determining the CMS for a colorectal cancer patient.
    Type: Application
    Filed: April 2, 2020
    Publication date: June 9, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventors: Jeffrey MORRIS, Scott KOPETZ, Dipen MARU, David G. MENTER
  • GENE MUTATIONS AND COPY NUMBER ALTERATIONS OF EGFR, KRAS AND MET
    Publication number: 20210395836
    Abstract: Sequence variants and copy number variations in the EGFR, KRAS and MET genes are biomarkers for resistance to anti-EGFR therapies for cancer. This disclosure provides methods of detecting these biomarkers and using them in the diagnosis and treatment of cancer.
    Type: Application
    Filed: July 22, 2021
    Publication date: December 23, 2021
    Inventors: Scott KOPETZ, AmirAli TALASAZ
  • Gene mutations and copy number alterations of EGFR, KRAS and MET
    Patent number: 11085086
    Abstract: Sequence variants and copy number variations in the EGFR, KRAS and MET genes are biomarkers for resistance to anti-EGFR therapies for cancer. This disclosure provides methods of detecting these biomarkers and using them in the diagnosis and treatment of cancer.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: August 10, 2021
    Assignee: Guardant Health, Inc.
    Inventors: Scott Kopetz, AmirAli Talasaz
  • GENE MUTATIONS AND COPY NUMBER ALTERATIONS OF EGFR, KRAS AND MET
    Publication number: 20190256927
    Abstract: Sequence variants and copy number variations in the EGFR, KRAS and MET genes are biomarkers for resistance to anti-EGFR therapies for cancer. This disclosure provides methods of detecting these biomarkers and using them in the diagnosis and treatment of cancer.
    Type: Application
    Filed: March 4, 2019
    Publication date: August 22, 2019
    Inventors: Scott KOPETZ, AmirAli TALASAZ
  • GENE MUTATIONS AND COPY NUMBER ALTERATIONS OF EGFR, KRAS AND MET
    Publication number: 20170145516
    Abstract: Sequence variants and copy number variations in the EGFR, KRAS and MET genes are biomarkers for resistance to anti-EGFR therapies for cancer. This disclosure provides methods of detecting these biomarkers and using them in the diagnosis and treatment of cancer.
    Type: Application
    Filed: November 10, 2016
    Publication date: May 25, 2017
    Inventors: Scott Kopetz, AmirAli Talasaz